Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study

BACKGROUND: Drug-induced interstitial lung disease (ILD) is one of the most serious adverse reactions associated with the molecularly targeted drugs. Panitumumab has been approved for advanced or recurrent colorectal cancer. Although there were no adverse reaction reports of ILD in panitumumab monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Masahiro, Kudoh, Shoji, Sakai, Fumikazu, Endo, Masahiro, Hamaguchi, Tetsuya, Ogino, Yumiko, Yoneoka, Miyo, Sakaguchi, Motonobu, Nishimoto, Hiroyuki, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666285/
https://www.ncbi.nlm.nih.gov/pubmed/25967287
http://dx.doi.org/10.1007/s10147-015-0834-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666285/
https://www.ncbi.nlm.nih.gov/pubmed/25967287
http://dx.doi.org/10.1007/s10147-015-0834-3

Ejemplares similares